» Articles » PMID: 37370940

Image Guided Radiotherapy (IGRT) and Delta (Δ) Radiomics-An Urgent Alliance for the Front Line of the War Against Head and Neck Cancers

Overview
Specialty Radiology
Date 2023 Jun 28
PMID 37370940
Authors
Affiliations
Soon will be listed here.
Abstract

The identification of a biomarker that is response predictive could offer a solution for the stratification of the treatment of head and neck cancers (HNC) in the context of high recurrence rates, especially those associated with loco-regional failure. Delta (Δ) radiomics, a concept based on the variation of parameters extracted from medical imaging using artificial intelligence (AI) algorithms, demonstrates its potential as a predictive biomarker of treatment response in HNC. The concept of image-guided radiotherapy (IGRT), including computer tomography simulation (CT) and position control imaging with cone-beam-computed tomography (CBCT), now offers new perspectives for radiomics applied in radiotherapy. The use of Δ features of texture, shape, and size, both from the primary tumor and from the tumor-involved lymph nodes, demonstrates the best predictive accuracy. If, in the case of treatment response, promising Δ radiomics results could be obtained, even after 24 h from the start of treatment, for radiation-induced xerostomia, the evaluation of Δ radiomics in the middle of treatment could be recommended. The fused models (clinical and Δ radiomics) seem to offer benefits, both in comparison to the clinical model and to the radiomic model. The selection of patients who benefit from induction chemotherapy is underestimated in Δ radiomic studies and may be an unexplored territory with major potential. The advantage offered by "in house" simulation CT and CBCT favors the rapid implementation of Δ radiomics studies in radiotherapy departments. Positron emission tomography (PET)-CT Δ radiomics could guide the new concepts of dose escalation on radio-resistant sub-volumes based on radiobiological criteria, but also guide the "next level" of HNC adaptive radiotherapy (ART).

Citing Articles

Bibliometric and visual analysis of radiomics for evaluating lymph node status in oncology.

Lyu G, Tong T, Yang G, Zhao J, Xu Z, Zheng N Front Med (Lausanne). 2024; 11:1501652.

PMID: 39610679 PMC: 11602298. DOI: 10.3389/fmed.2024.1501652.


Cone beam computed tomography (CBCT) and megavoltage computed tomography (MVCT)-based radiomics in head and neck cancers: a systematic review and radiomics quality score assessment.

Ismail M, Hanifa M, Mahidin E, Manan H, Yahya N Quant Imaging Med Surg. 2024; 14(9):6963-6977.

PMID: 39281127 PMC: 11400681. DOI: 10.21037/qims-24-334.

References
1.
Rades D, Warwas B, Gerull K, Pries R, Leichtle A, Bruchhage K . Prognostic Factors for Complete Recovery From Xerostomia After Radiotherapy of Head-and-Neck Cancers. In Vivo. 2022; 36(4):1795-1800. PMC: 9301398. DOI: 10.21873/invivo.12894. View

2.
Tao Y, Biau J, Sun X, Sire C, Martin L, Alfonsi M . Pembrolizumab versus cetuximab concurrent with radiotherapy in patients with locally advanced squamous cell carcinoma of head and neck unfit for cisplatin (GORTEC 2015-01 PembroRad): a multicenter, randomized, phase II trial. Ann Oncol. 2022; 34(1):101-110. DOI: 10.1016/j.annonc.2022.10.006. View

3.
Yan D . Adaptive radiotherapy: merging principle into clinical practice. Semin Radiat Oncol. 2010; 20(2):79-83. DOI: 10.1016/j.semradonc.2009.11.001. View

4.
Wang X, Xie T, Luo J, Zhou Z, Yu X, Guo X . Radiomics predicts the prognosis of patients with locally advanced breast cancer by reflecting the heterogeneity of tumor cells and the tumor microenvironment. Breast Cancer Res. 2022; 24(1):20. PMC: 8922933. DOI: 10.1186/s13058-022-01516-0. View

5.
Sturgis E, Miller R . Second primary malignancies in the head and neck cancer patient. Ann Otol Rhinol Laryngol. 1995; 104(12):946-54. DOI: 10.1177/000348949510401206. View